Drug Profile


Alternative Names: FVH-1; FVH1 (DNA-based influenza vaccine) - Inovio; Influenza H1N1 seasonal influenza vaccine - Inovio; INO 3605; INO 3609; SynCon® H1HA consensus DNA vaccine - Inovio; SynCon® universal H1N1 influenza vaccine - Inovio

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class Influenza A virus H1N1 vaccines; Influenza virus DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(In the elderly, Prevention, In volunteers) in Canada (Intradermal, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention, In volunteers) in USA (Intradermal, Injection)
  • 01 Mar 2015 Inovio Pharmaceuticals and University of Manitoba complete enrolment in its Phase-I trial for Influenza-A virus H1N1 subtype (prevention in elderly volunteers) in Canada (NCT01587131)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top